Acquisition / mergerFiled on NSE ·
Q-Line Biotech reports H1 FY27 financial results with 5.83% revenue growth
₹152 CrAcquisition / merger
Key highlights
- H1 FY27 revenue ₹152.18 crore, up 5.83% YoY; EBITDA ₹39.57 crore, up 10.02%, margin 26.00%
- Profit after tax ₹19.60 crore, down 8.06%, impacted by higher depreciation from new Unit 4 facility
- Proposed acquisition of 70% stake in Heidelco Medicore Pvt Ltd for ₹26.63 crore approved by Board
Original filing
Press Release
Read the filing on NSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Rossell Techsys
Aerospace & Defense
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Q-Line Biotech
Other acquisition / merger filings this fortnight
- Acquisition / mergerFusion CXFusion CX Ltd's UK subsidiary to acquire 3 German BPO firms for €2 million
- Acquisition / mergerOrganic Recycling SystemsOrganic Recycling Systems Ltd announces Board approvals on Nov 12, 2026
- Acquisition / mergerPushpa JewellersPushpa Jewellers reports strong H1 FY27 results with 83% income growth
- Acquisition / mergerSkyways Air ServicesSkyways Air Services increases stake in Forin Container Line and Brace Port reports H1 FY27 results
- Acquisition / mergerSkyways Air ServicesSkyways Air Services invests ₹42.42 crore in Forin Container; Brace Port reports H1 FY27 results
- Acquisition / mergerFlywings Simulator Training CentreFlywings approves acquisition of 46.74% stake in Shree OSFM E-Mobility Limited
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.